What is Indo US Bio-Tech Ltd (INDOUS) share price return in the past 10 years?

Data is not available for this company

What is the share price of Indo US Bio-Tech Ltd (INDOUS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Indo US Bio-Tech Ltd (INDOUS) on 05-Jun-2026 16:59:59 at 16:59 is 97.60.

What is the P/E ratio of Indo US Bio-Tech?

The latest standalone P/E ratio of Indo US Bio-Tech as of 05-Jun-2026 is 14.97.

What is the P/B ratio of Indo US Bio-Tech Ltd (INDOUS)?

The latest standalone P/B ratio of Indo US Bio-Tech Ltd (INDOUS) as of 05-Jun-2026 is 2.12.

What is the 52-week high and low of Indo US Bio-Tech Ltd (INDOUS)?

The 52-week high of Indo US Bio-Tech Ltd (INDOUS) is Rs. 205.10 and the 52-week low is Rs. 94.00.

Indo US Bio-Tech Ltd (INDOUS) Share Analysis – Quality, Growth & Valuation Zone & DeciZen Rating

Name: Indo US Bio-Tech Ltd (INDOUS)
Brand: Indo US Bio-Tech

Indo US Bio-Tech Ltd (INDOUS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 541304 NSE: INDOUS Agriculture | Small Cap | Indo US Bio-Tech Share Price

Indo US Bio-Tech Ltd (INDOUS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 541304 NSE: INDOUS Agriculture | Small Cap | Indo US Bio-Tech Share Price

Key Metrics

Valuation Multiples

Market Cap

₹197 Cr.

Current Price

₹97.6

52-Week Low / High

₹94 / 205

TTM EPS

₹6.5

TTM Sales

₹110 Cr.

Book Value per Share

₹46.2

P/E Ratio

14.97

Lower than its 5-year historical median

Industry PE

15.5

Price to Book (P/B)

2.12

Lower than its 5-year historical median

Price to Sales (P/S)

1.78

Lower than its 5-year historical median

EV/EBITDA

13.33

Lower than its 5-year historical median

Dividend Yield

0.17%

Profitability Efficiency

Return on Equity (ROE)

23.03%

Outperforms industry median

Return on Capital Employed (ROCE)

21.15%

Outperforms industry median

Return on Assets (ROA)

17.98%

Operating Profit Margin

18.2%

Net Profit Margin

15.67%

Gross Profit Margin

17%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

42.56%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

75.37%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

97.21%

Asset Quality

Promoter Holding

68.29%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹72 Cr.

Equity

₹20.1 Cr.

Face Value

₹10

All Time Low / High

₹12.85 / 386.00

Indo US Bio-Tech stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Somewhat Undervalued

Check Valuation charts

Price Trend

Weak

Check Price chart

Q.1 Is Indo US Bio-Tech Ltd a good quality company?

Indo US Bio-Tech Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Indo US Bio-Tech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Indo US Bio-Tech Ltd vs industry peers?

Indo US Bio-Tech Ltd revenue CAGR is 21.17%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Indo US Bio-Tech Ltd?

Promoters hold 68.29% of the Indo US Bio-Tech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Indo US Bio-Tech Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 45.98% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	7.4%	14.2%	27.8%	20.4%	16.7%	18.3%	15.9%	14.6%	14.4%	21.2%	-
Value Creation Index ⓘ	-0.5	0.0	1.0	0.5	0.2	0.3	0.1	0.0	0.0	0.5	-
Growth Parameters ⓘ
Sales ⓘ	19.1	24.5	29.6	35.5	39.8	40.1	50.1	61.7	72.8	104	110
Sales YoY Gr.	-	28.7%	20.9%	19.8%	12%	0.8%	24.8%	23.4%	18%	42.6%	-
Adj EPS ⓘ	0.4	0.4	1.5	1.5	1.8	3.5	2.9	3.6	4.1	8.1	6.5
YoY Gr.	-	11.4%	292.3%	-1.3%	15.9%	100%	-18.3%	26.2%	14.1%	96.8%	-
BVPS (₹) ⓘ	3.2	3.4	4.8	9.5	11.3	14.8	21.2	27.2	31.3	39.2	46.2
Adj Net Profit ⓘ	0.4	0.4	1.6	2.2	2.6	5.1	5.2	7.2	8.3	16.3	13
Cash Flow from Ops. ⓘ	-2.6	0.1	-0.9	-3.2	-0.8	0.2	2.9	0.5	-4.6	1.4	-
Debt/CF from Ops. ⓘ	-1.8	71.5	-7.4	-2	-10.2	51	4.3	22.1	-3.1	10.5	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	20.7%	21.2%	27.5%	42.6%
Adj EPS ⓘ	41.8%	35.9%	41.5%	96.8%
BVPSⓘ	32.2%	28.3%	22.7%	25.2%
Share Price	-	44.6%	-5.2%	-40.1%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	11.7	11.7	37.2	23.3	16.8	26.9	17.3	15.5	14.1	23	15.3
Op. Profit Mgn % ⓘ	2.7	5.1	9.7	10.1	10	13.8	13.9	15.2	14.8	18.2	15.4
Net Profit Mgn % ⓘ	1.9	1.6	5.3	6.2	6.4	12.7	10.5	11.7	11.3	15.7	11.9
Debt to Equity ⓘ	1.4	1.4	1.3	0.5	0.5	0.5	0.3	0.2	0.2	0.2	0
Working Cap Days ⓘ	173	170	161	188	243	322	314	317	331	279	182
Cash Conv. Cycle ⓘ	84	84	102	146	173	214	255	271	295	265	127

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	19	25	30	35	40	40	50	62	73	104
Operating Expenses ⓘ +	19	23	27	32	36	35	43	52	62	85
Manufacturing Costs	1	0	2	7	29	29	48	46	77	79
Material Costs	17	20	23	22	4	0	-9	2	-20	2
Employee Cost	0	0	0	0	0	0	0	1	1	1
Other Costs ⓘ	1	2	2	2	2	5	4	3	3	4
Operating Profit ⓘ	1	1	3	3	4	6	7	9	11	19
Operating Profit Margin (%)	2.7%	5.1%	9.1%	9.6%	10.0%	13.8%	13.8%	15.2%	14.8%	18.2%
Other Income ⓘ +	0	0	0	0	0	0	0	0	0	0
Exceptional Items ⓘ	0	0	0	-0	-0	0	0	0	0	0
Interest ⓘ	0	1	1	0	1	1	1	1	2	1
Depreciation ⓘ	0	0	0	0	0	0	0	1	1	1
Profit Before Tax ⓘ	0	1	2	3	3	4	5	7	9	17
Tax ⓘ	-0	0	1	1	0	-1	0	0	1	0
Profit After Tax	0	0	1	2	3	5	5	7	8	16
PAT Margin (%)	1.9%	1.6%	4.9%	5.9%	6.4%	12.7%	10.5%	11.7%	11.3%	15.7%
Adjusted EPS (₹)	0.4	0.4	1.4	1.4	1.7	3.5	2.9	3.6	4.1	8.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	3.10%

Valuation of Indo US Bio-Tech - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3	3	5	14	16	22	39	54	63	79
Share Capital ⓘ	1	1	3	5	6	6	9	10	20	20
Reserves ⓘ	2	2	2	9	10	15	30	44	43	58
Debt +	5	5	6	5	8	11	10	10	13	13
Long Term Debt	0	0	1	1	1	3	3	2	3	3
Short Term Debt	4	4	5	5	7	7	7	8	10	10
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	5	4	5	2	8	9	2	1	4	1
Others Liabilities ⓘ	-0	0	1	2	2	2	4	3	3	4
Total Liabilities ⓘ	13	12	17	24	35	43	55	69	84	97
Fixed Assets
Net Fixed Assets ⓘ +	1	1	2	1	1	2	6	7	7	10
Gross Block	2	2	2	3	1	2	6	7	7	15
Accumulated Depreciation	1	1	0	1	0	0	0	0	0	4
CWIP ⓘ	0	0	0	1	1	2	2	1	4	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	5	5	6	11	9	12	23	27	52	71
Trade Receivables	6	5	9	9	21	25	21	25	19	15
Cash Equivalents	0	0	0	0	0	0	0	0	1	0
Others Assets ⓘ	1	1	0	1	2	2	3	8	1	1
Total Assets ⓘ	13	12	17	24	35	43	55	69	84	97

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-3	0	-1	-3	-1	0	3	1	-5	1
PBT ⓘ	0	1	2	3	3	4	5	7	9	17
Adjustment ⓘ	0	0	1	1	1	1	2	2	2	3
Changes in Working Capital ⓘ	-3	-1	-3	-7	-5	-5	-4	-9	-15	-18
Tax Paid ⓘ	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Cash Flow From Investing Activity ⓘ +	-0	-0	0	-3	-1	-2	-5	-7	4	-1
Capex	-0	-0	-0	-1	-0	-2	-4	-2	-3	-1
Net Investments	0	0	0	0	0	-0	0	0	0	0
Others ⓘ	0	0	1	-1	-0	0	-1	-5	7	0
Cash Flow From Financing Activity ⓘ +	3	0	1	6	2	1	2	6	1	-1
Net Proceeds from Shares ⓘ	0	0	0	7	0	0	3	8	0	0
Net Proceeds from Borrowing ⓘ	-0	0	1	-1	-0	3	0	-2	1	0
Interest Paid ⓘ	-0	-0	-1	-0	-1	-1	-1	-1	-2	-1
Dividend Paid ⓘ	0	0	0	0	0	0	-0	0	0	-1
Others ⓘ	3	0	0	-0	3	0	1	1	2	0
Net Cash Flow ⓘ	0	-0	0	0	0	-0	-0	0	1	-1

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	11.69	11.74	34.36	22.21	16.74	26.87	17.34	15.51	14.08	23.03
ROCE (%)	7.39	14.24	27.84	20.35	16.65	18.3	15.86	14.62	14.42	21.15
Asset Turnover Ratio	1.88	1.95	2.05	1.74	1.36	1.03	1.02	1	0.95	1.15
PAT to CFO Conversion(x)	N/A	N/A	-1	-1.5	-0.33	0	0.6	0.14	-0.63	0.06
Working Capital Days
Receivable Days	66.20	79.40	86.60	92.80	137.90	207.90	164.90	133.90	109.70	59.80
Inventory Days	90.50	78	69.90	87	91.20	95.70	128.50	148.60	197.10	215.20
Payable Days	86	79.10	63.90	54.20	418.40	0	-222.50	302.50	-53.90	597.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Indo US Bio-Tech Ltd FAQs

The current trading price of Indo US Bio-Tech on 05-Jun-2026 16:59 is ₹97.60.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Indo US Bio-Tech stood at ₹196.5 Cr

The latest P/E ratio of Indo US Bio-Tech as of 04-Jun-2026 is 14.97.

The latest P/B ratio of Indo US Bio-Tech as of 04-Jun-2026 is 2.12.

The 52-week high of Indo US Bio-Tech is ₹205.1 and the 52-week low is ₹94.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Indo US Bio-Tech is ₹110 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Indo US Bio-Tech Ltd is a average quality company.

The key valuation ratios of Indo US Bio-Tech Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Indo US Bio-Tech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Indo US Bio-Tech Ltd

No data to display

Indo US Bio-Tech Ltd (INDOUS)

Indo US Bio-Tech Ltd (INDOUS)

Indo US Bio-Tech stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Indo US Bio-Tech - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Indo US Bio-Tech Ltd FAQs

About Indo US Bio-Tech Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Indo US Bio-Tech Ltd (INDOUS)

Indo US Bio-Tech Ltd (INDOUS)

Indo US Bio-Tech stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Indo US Bio-Tech - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Indo US Bio-Tech Ltd FAQs

What is the share price of Indo US Bio-Tech?

What is the market cap of Indo US Bio-Tech?

What is the P/E ratio of Indo US Bio-Tech?

What is the P/B ratio of Indo US Bio-Tech?

What is the 52-week high and low of Indo US Bio-Tech?

What is the TTM revenue of Indo US Bio-Tech?

Is Indo US Bio-Tech Ltd a good quality company?

Is Indo US Bio-Tech Ltd undervalued or overvalued?

Is Indo US Bio-Tech Ltd a good buy now?

About Indo US Bio-Tech Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.